The you, characterized progress us to for afternoon Hey. for Arcturus. and has at by here period all. you today's Thank Neda, Thank substantial good operational pipeline call. recent been joining and
will be We highlighting four update call. areas today's on
with at the Seqirus year. collaboration end CSL First, agreement we vaccine our closed last strategic of
seasonal on invoiced vaccine payment COVID million that partnered Demonstrating upfront We additional million companies positive and $XX the our have the flu made received $XXX and programs. progress the in have milestones.
as ARCT-XXX report SARS-CoV-X as providing an agreement very with an for Pharma be progress COVID-XX. in there. we'll a known the and significant in Phase operational And vaccine booster to ongoing X we're Japan entered evaluate update to happy also we've into study Second, Meiji
have progress our provide will stage to on there. programs, an recent update our and RNA technology earlier we platform and Third, advance continued clinical we
by our Smolenov, overseeing team development as Officer, Development Juergen strengthened the Igor Froehlich addition Medical of our mRNA our of franchise. Fourth, as management Officer, Chief Chief Dr. we have overseeing and vaccine Dr. our clinical therapeutics
strategic I'll collaboration with begin recently our with announced CSL.
in are how Arcturus of substantial associated phase together. four-month-old has pleased teams milestones flu initial candidates the are seasonal our with collaboration and working with this for achieved very next-generation We the programs. COVID and nominating month now
groups these Mutual and working to of is for eligible that pipeline development early remain and both execution milestones solid We commercial additional There led clear ethic respect passion a is between advance. behind important the milestones achieved. evident companies. as work and covered competent the has being programs
vaccines the additional collaboration pandemic preparedness. of CSL COVID, Our pathogens next commercialization three on generation with is as well mRNA targeting and focused as development Influenza,
the LUNAR collaboration manufacturing Arcturus’ and technologies. and vaccine, manufacturing CSL's platform Our infrastructure with expertise commercial STAR combines vaccine mRNA delivery mRNA established and well global innovative
that and We this and Andy the next commercialization balance of be our generation be expect sheet self-amplifying to of drive impact collaboration to to over to this collaboration will vaccines shortly. years. global The the coming runway and development, speaking meaningful mRNA continues manufacture
to Meiji on in development with Now to agreement Japan. our ARCT-XXX advance Pharma
Meiji with ARCT-XXX. next developing vaccine COVID-XX. booster is relationship contracted Our self-amplifying generation focused This mRNA is our for on
booster appreciate the highest one already Japan world's rates COVID may that has You of of vaccination.
utilization Given high for expect and the of years focus we Japanese levels government's fully come. health prevention, public disease to infectious on many booster COVID
with clear in Japanese in and has interest the of this establishing to mRNA been effort very their Meiji. pleased government about be part vaccines In we're addition, independence
related for Japan. from subsidy effort all government significant a ARCT-XXX in of quarter the received development in is the Group Japanese to costs Meiji and XXXX this to fourth responsible Meiji support
on there. non-inferiority and we've and appreciative that study Japan Comirnaty targeting enrollment seen compare in participants with moved booster Meiji productivity and with ARCT-XXX In X designed Phase Meiji to progress immunogenicity. December based initiated the quickly impressed to XXXX, announced had process, we XXX the a very adult
today I'm target report of the is and very with schedule. over pleased participants, enrollment XXX to study ahead enrolled that now exceeding our fully
month draws This have NDA blood pre-requisite file visits be Japan. In immunogenicity one been and first to allows position the the addition, execution to one follow-up timely data collect a the in month completed. our immediately in and us also potentially
that potentially cycle investigational crises improve this stage Now with begin life the to OTC activity address ornithine strict moving urea our quality cause I'll with deficiency and disease. the OTC the for protein to This restore deficiency. to prevent damage and candidate living of our livers therapeutic condition. deficient dietary in of and is potential programs enzyme for This with ARCT-XXX. and liberalize therapeutic ARCT-XXX or earlier individuals transcarbamylase metabolic this neurological people the has restrictions aims
favorable our safety delivery lipids attribute the profile. are that this utilizes program proprietary The and a administered to one LUNAR contribute degraded, important is technology technology which we will of expect rapidly
Phase studies that in ARCT-XXX a We study a when profile dosed safety the completed a that and multi-dose X.X favorable evaluating in demonstrated upon X deficiency Xb a OTC X build per and Difficulty] studies, dose study. kilogram, ongoing clinical [Technical adults Phase two These in with Phase highest up are adolescents evaluated study to megs in adults study
cohorts. this OTC study. to living clinical two with ARCT-XXX interim study We to XX X will Phase We across later report subjects. study in enrolled The up the distributed Phase adolescents remain deficiency advance dose data multiple The and track ARCT-XXX on year. has X continue adults enroll to
on ARCT-XXX, to individuals we the cystic lungs this fibrosis. cystic in of functional messenger fully Now for our protein this CFTR candidate with aiming drug, is moving With express to RNA inhaled therapeutic are fibrosis.
provide with disease across underlying CF by that agnostic is of who approach benefit not believe associated well for to those served therapies. and with we CFTR Our could ARCT-XXX and range mutations CF, the X very Type a wide the especially are modulator individuals living
investigational medicine. of promising to support for this We're have the obtained grateful the Foundation CF from advancement
the with from benefit scientific invaluable CF at also We the experts collaboration Foundation.
four epithelium in disease delivery in mice, the ferrets with successful patients airways, lung deliver in preclinical significant have similar primates. species: rats, produces CF airway Previously, to the variant. shown to data different our to ability reported is we model mucus This a and the mRNA Notably, animal data encouraging CF. to that the demonstrating
Finally, with robust CF dose evaluating ARCT-XXX cells has in-vitro from protein now treatment Phase of in different of donors study conducted Supported a being restoration encouraging Zealand. these demonstrated bronchial in four current. by CFTR expression we levels epithelial chloride are New and ARCT-XXX I at of data,
entire to enrollment later report We this quarter year. second results the with and cohorts study subject completed first of this have year study successfully plan the expectation the enrollment complete two the XX in of to of
our to month. Arcturus share next is excited data LUNAR-HBV
We have editing years. platform in-vivo our optimizing been intravenously gene dosed for
presented gene gene opportunity scientific editing Hepatitis to on hepatitis XX evaluate XXth the preclinical for B Arcturus' mRNA Annual Global of community editing the will systemically April This virus applications. LUNAR for data Conference Our be at the benefits delivery Summit be in of first Paris, the mRNA platform or will France. administered
quarter, our In management have this team. strengthened past we
for on have lead Igor our COVID Juergen and and Officer to promising Froehlich, brought be our our Chief pipeline Dr. seasonal to brought our flu mRNA our on have also leadership who Development We to be provide self-amplifying efforts over our CMO, will Dr. therapeutics seasoned Officer, clinical board mRNA development Smirnoff Arcturus' Chief Medical vaccines.
clinical our deficiency Genevant. therapeutic successful will decades Froehlich field of increase in and of clinical cystic and broad as the and trials He OTC experience diseases, rare Now including fibrosis. of He three navigates Dr. Vertex our late-stage and assuredly and initiates success Quintiles, rare likelihood BMS, disease development therapeutic through at broad Genentech, has programs. late-stage for Ipsen, Arcturus experience has
of School and Medical at Pharmacology the Zurich, Albany. Wartburg in global at Canada, a State the European has York Diplomat he drugs in U.S., American marketing the of is holds executive MBA dual directly Switzerland Germany, of the University of Clinical Switzerland Jurgen successful in been completed University Juergen Australia. involved a and Union, of the from Board New and authorizations
X infection. been trials XXXX, other including Since therapeutics early X modulators. to approval he's with late-stage and patients inhaled development lung in treat clinical Phase X, of the seasoned KALYDECO and and planning in has development CF with of He CF chronic for experience CFTR involved in therapeutics,
as are Officer. Medical management have We join Chief to Froehlich, team fortunate Dr. our Juergen our
of and large accomplishment and Now excited programs all in moving to Vaccines, next record vaccine through Dr. clinical of record and and about to our with the team of Development partnership way vaccines COVID our we're innovative get vaccines. recognized in leader help introduce that. a development Igor the strong successfully development has a biotech He CSL, this of proven developing successful a licensure with several Officer contributed Smolenov Chief is our on approval. flu our companies. to pharmaceutical level, Smolenov He will and Dr.
to that vaccine and leading Vice President Executive a Before Smolenov clinical That's generate rapidly joining he data, pivotal team authorization launch Clover Dr. the able built COVID-XX a strong where was Arcturus, at there. Pharmaceuticals. was product to
Before Smolenov CSL RNA as managing Moderna, of that, several the initiation the vaccines the head, Igor served therapeutic first a clinical leading at Development development Seqirus. at area flu of seasonal vaccines trials the Head of Clinical Dr. was of in messenger humans.
in multiple Russia, where graduated XX and the from contributed At university. as licensure of than He's vaccine University clinical Doctor infectious well. global from and PhD vaccines a degrees more in Novartis the MD, Smolenov there in Science development pharmacology, he of an development. journals peer-reviewed Dr. State Vaccines, Igor of and Volgograd to publications Medical a this holds disease author
our Arcturus vaccine We CDI are Dr. Igor indeed Smolenov overseeing here fortunate as at franchise. team our to have our join
to call I provide will to the CFO, Sassine, pass now Andy our updates. financial on
